stockrowIovance Biotherapeutics, Inc.
IOVA Healthcare Biotechnology
Iovance Biotherapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $263.5 million, up 60.6% from fiscal 2024.
- Revenue
- +80.1%
- EPS
- +80.0%
- Free cash flow
- +89.7%
Quarter to September 2026, against a year earlier
Follow IOVA
Alert me
Iovance Biotherapeutics, Inc. (IOVA) Total debt
Iovance Biotherapeutics, Inc.'s total debt at the end of fiscal 2024 was $1.0M, unchanged from fiscal 2023. Over the past ten years it has ranged from $1.0M (fiscal 2024) to $4.2M (fiscal 2019) — the current reading is the lowest in ten years. Iovance Biotherapeutics, Inc. ranks 388th of 569 Biotechnology companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2024 | $1.0M | 0.00% |
| FY2023 | $1.0M | 0.00% |
| FY2022 | $1.0M | 0.00% |
| FY2021 | $1.0M | (76.46%) |
| FY2019 | $4.2M | — |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Dec 2024 | $1.0M | 0.00% |
| Sep 2024 | $1.0M | 0.00% |
| Jun 2024 | $1.0M | 0.00% |
| Mar 2024 | $1.0M | 0.00% |
| 18 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| ABCL AbCellera Biologics Inc. compare | $81.0M |
| IRON Disc Medicine, Inc. compare | $59.3M |
| RLAY Relay Therapeutics, Inc. compare | $55.0M |
| ACAD ACADIA Pharmaceuticals Inc. compare | $48.1M |
| TNGX Tango Therapeutics, Inc. compare | $39.5M |
| XENE Xenon Pharmaceuticals Inc. compare | $11.0M |
| PBLS Parabilis Medicines, Inc. compare | $6.8M |
| EWTX Edgewise Therapeutics, Inc. compare | $5.6M |
| IOVA Iovance Biotherapeutics, Inc. | $1.0M |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on IOVA
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Altman Z-score
- The full statement